Carlton Hofferkamp & Jenks Wealth Management LLC Sells 200 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Carlton Hofferkamp & Jenks Wealth Management LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,550 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Gilead Sciences were worth $588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Carrera Capital Advisors increased its position in shares of Gilead Sciences by 23.6% during the 3rd quarter. Carrera Capital Advisors now owns 25,546 shares of the biopharmaceutical company’s stock valued at $2,142,000 after purchasing an additional 4,886 shares during the last quarter. Aptus Capital Advisors LLC boosted its stake in Gilead Sciences by 3.9% in the third quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 309 shares in the last quarter. Commonwealth Retirement Investments LLC grew its position in Gilead Sciences by 8.1% during the third quarter. Commonwealth Retirement Investments LLC now owns 24,510 shares of the biopharmaceutical company’s stock valued at $2,055,000 after acquiring an additional 1,828 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Gilead Sciences by 1.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,023,984 shares of the biopharmaceutical company’s stock worth $253,531,000 after acquiring an additional 55,841 shares in the last quarter. Finally, FDx Advisors Inc. lifted its holdings in shares of Gilead Sciences by 2.2% in the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $91.50.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 2.8 %

GILD stock opened at $94.35 on Wednesday. The company has a market capitalization of $117.46 billion, a price-to-earnings ratio of 1,048.33, a price-to-earnings-growth ratio of 3.01 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.82 and a current ratio of 1.11. The business’s 50 day moving average price is $85.95 and its two-hundred day moving average price is $75.57. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.